Cargando…

Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis

Multiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS). Although immune modulation and suppression are effective during relapsing-remitting MS, secondary progressive MS (SPMS) requires neuroregenerative therapeutic options that act on the CNS. The sphingosine-1-phosphat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weier, Alicia, Enders, Michael, Kirchner, Philipp, Ekici, Arif, Bigaud, Marc, Kapitza, Christopher, Wörl, Jürgen, Kuerten, Stefanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695324/ https://www.ncbi.nlm.nih.gov/pubmed/36430692 http://dx.doi.org/10.3390/ijms232214209

Ejemplares similares

Murine Esophagus Expresses Glial-Derived Central Nervous System Antigens
por: Kapitza, Christopher, et al.
Publicado: (2021)

Nimodipine Exerts Beneficial Effects on the Rat Oligodendrocyte Cell Line OLN-93
por: Boltz, Felix, et al.
Publicado: (2022)

Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis
por: Brand, Rosa Margareta, et al.
Publicado: (2021)

Siponimod (BAF312) penetrates, distributes, and acts in the central nervous system: Preclinical insights
por: Bigaud, Marc, et al.
Publicado: (2021)

Siponimod ameliorates experimental autoimmune neuritis
por: Uchi, Takafumi, et al.
Publicado: (2023)

Splitting the “Unsplittable”: Dissecting Resident and Infiltrating Macrophages in Experimental Autoimmune Encephalomyelitis
por: Koeniger, Tobias, et al.
Publicado: (2017)

Impact of the Voltage-Gated Calcium Channel Antagonist Nimodipine on the Development of Oligodendrocyte Precursor Cells
por: Enders, Michael, et al.
Publicado: (2023)

The next-generation sphingosine-1 receptor modulator BAF312 (siponimod) improves cortical network functionality in focal autoimmune encephalomyelitis
por: Hundehege, Petra, et al.
Publicado: (2019)

Central Versus Peripheral Drug Exposure Ratio, a Key Differentiator for Siponimod Over Fingolimod?
por: Bigaud, Marc, et al.
Publicado: (2023)

Conventional Housing Conditions Attenuate the Development of Experimental Autoimmune Encephalomyelitis
por: Arndt, Andreas, et al.
Publicado: (2014)

Does Siponimod Exert Direct Effects in the Central Nervous System?
por: Kipp, Markus
Publicado: (2020)

Increased Remyelination and Proregenerative Microglia Under Siponimod Therapy in Mechanistic Models
por: Dietrich, Michael, et al.
Publicado: (2022)

Siponimod for multiple sclerosis
Publicado: (2021)

Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis
por: Prinz, Johanna, et al.
Publicado: (2015)

Correction: Time-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis
por: Prinz, Johanna, et al.
Publicado: (2016)

Effect of Siponimod on Brain and Spinal Cord Imaging Markers of Neurodegeneration in the Theiler’s Murine Encephalomyelitis Virus Model of Demyelination
por: Pol, Suyog, et al.
Publicado: (2023)

Partial Deficiency of Sphingosine-1-Phosphate Lyase Confers Protection in Experimental Autoimmune Encephalomyelitis
por: Billich, Andreas, et al.
Publicado: (2013)

Antibody cross-reactivity between casein and myelin-associated glycoprotein results in central nervous system demyelination
por: Chunder, Rittika, et al.
Publicado: (2022)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action
por: Behrangi, Newshan, et al.
Publicado: (2019)

Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2020)

CEACAM1 mediates B cell aggregation in central nervous system autoimmunity
por: Rovituso, Damiano M., et al.
Publicado: (2016)

Immune monitoring of SARS-CoV-2-specific T cell and B cell responses in patients with multiple sclerosis treated with ocrelizumab
por: Groß-Albenhausen, Elina, et al.
Publicado: (2023)

Localization of near-infrared labeled antibodies to the central nervous system in experimental autoimmune encephalomyelitis
por: Lee, Sangmin, et al.
Publicado: (2019)

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2021)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Migraine, interferon β1a and siponimod immunomodulator therapies
por: Dahaba, Ashraf A., et al.
Publicado: (2022)

Siponimod Modulates the Reaction of Microglial Cells to Pro-Inflammatory Stimulation
por: Gruchot, Joel, et al.
Publicado: (2022)

Sustained TNF production by central nervous system infiltrating macrophages promotes progressive autoimmune encephalomyelitis
por: Valentin-Torres, Alice, et al.
Publicado: (2016)

Danger: High Voltage—The Role of Voltage-Gated Calcium Channels in Central Nervous System Pathology
por: Schampel, Andrea, et al.
Publicado: (2017)

Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
por: Regner-Nelke, Liesa, et al.
Publicado: (2022)

Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis
por: Gentile, Antonietta, et al.
Publicado: (2016)

Impact of siponimod on vaccination response in a randomized, placebo-controlled study
por: Ufer, Mike, et al.
Publicado: (2017)

COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series
por: Sullivan, Roseanne, et al.
Publicado: (2021)

The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis
por: Cohan, Stanley L., et al.
Publicado: (2022)

Targeting central nervous system extracellular vesicles enhanced triiodothyronine remyelination effect on experimental autoimmune encephalomyelitis
por: Xiao, Yun, et al.
Publicado: (2021)

Strategies for Neuroprotection in Multiple Sclerosis and the Role of Calcium
por: Enders, Michael, et al.
Publicado: (2020)

R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice
por: Schmitz, Katja, et al.
Publicado: (2014)

Calbindin D28k-Immunoreactivity in Human Enteric Neurons
por: Zetzmann, Katharina, et al.
Publicado: (2018)

Amelioration of Experimental Autoimmune Encephalomyelitis by Anatabine
por: Paris, Daniel, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_lulsmrhlfkh2a6l97sghjf1dl7